Optimized human cell products for research
and drug discovery

Custom Disease Model – Patient Derived

It is known that genetic variability in donors can influence the capacity of donor material to generate truly pluripotent lines that can effectively differentiate in to “end” cell types. DefiniGEN projects are structured to ensure the client recieves their desired custom cell disease model by using multiple donors and clonal lines with the lines being assessed and ranked at each stage to ensure that the best line is used in large scale custom cell model production.

  • DefiniGEN can source a disease patient sample for iPSC line generation or use an existing iPSC line from Corriell, EBiSC (European Bank for iPSC) and additional cell banks
  • Client recieves fully differentiated rigorously QCed cell products which are genotype and phenotype verified in a highly relevant physiological background


Definigen OptiDIFF Platform


European Bank for iPSCCoriell Institute


Patient Derived Custom Disease Model


Custom Disease Model – Patient Derived projects are typically completed within 4-6 months. Actual timelines will vary depending on the unique aspects of each bespoke project.

Selected platform publications

Generation of Hepatocytes from Pluripotent Stem Cells for Drug Screening and Developmental Modeling. Gieseck RL 3rd, Vallier L, Hannan NR. Methods Mol Biol. 2015;1250:123-42.

Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Sampaziotis F, Vallier L et al Nature Biotechnol. 2015 Aug; 33(8): 845–852.

Generation of Distal Airway Epithelium from Multipotent Human Foregut Stem Cells. Hannan NR, Sampaziotis F, Segeritz CP, Hanley NA, Vallier L. Stem Cells Dev. 2015 Jul 15;24(14):1680-90.

Production of hepatocyte-like cells from human pluripotent stem cells. Hannan NR, Vallier L et al. Nature Protocols. 2013 Feb;8(2):430-7.

Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells. Cho C , Hannan NR, Vallier L et al. Diabetologia. 2012 Dec 55(12):3284-95.

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Yusa K, Rashid ST, Vallier L et al. Nature. 2011 Oct 12;478(7369):391-4.

Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. Rashid ST, Lomas DA, Vallier L et al. J Clin Invest. 2010 Sep;120(9):3127-36.

Contact us to find out more

Please provide brief description here.